ORIGINAL ARTICLE

Mean Platelet Volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity

Gulali Aktas , Mehmet Zahid Kocak, Tuba Taslamacioglu Duman, Edip Erkus, Burcin Meryem Atak, Mustafa Sit, Haluk Savli

Gulali Aktas
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey. Email: [email protected]

Mehmet Zahid Kocak
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey

Tuba Taslamacioglu Duman
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey

Edip Erkus
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey

Burcin Meryem Atak
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey

Mustafa Sit
Abant Izzet Baysal University Hospital, Department of General Surgery, Bolu, Turkey

Haluk Savli
Abant Izzet Baysal University Hospital, Department of Internal Medicine, Bolu, Turkey
Online First: October 03, 2018 | Cite this Article
Aktas, G., Kocak, M., Taslamacioglu Duman, T., Erkus, E., Atak, B., Sit, M., Savli, H. 2018. Mean Platelet Volume (MPV) as an inflammatory marker in type 2 diabetes mellitus and obesity. Bali Medical Journal 7(3). DOI:10.15562/bmj.v7i3.806


Background: Type 2 diabetes mellitus and obesity are two important disorders which are associated with the enormous amount of morbidity and mortality. Inflammation plays a crucial role in development and complications of these diseases. Aim: We aimed to compare mean platelet volume (MPV) as an inflammatory marker in well and poorly controlled type 2 diabetic subjects and to observe its association with obesity indices, body mass index (BMI) and waist circumference. Method: Data of type 2 diabetic patients obtained from institutional database retrospectively analyzed. Patients were divided into two groups according to the HbA1c level as follows: HbA1c lower than 7% were classified as well-controlled, and HbA1c equal to or greater than 7% were classified as poorly controlled diabetics. Result: Both MPV, body mass index (BMI) and waist circumference were significantly higher in poorly controlled diabetics compared to patients with well-controlled type 2 DM. Conclusion: MPV could be considered as a marker of inflammatory burden in type 2 DM and obesity. Due to its cost-effective and easy to assess nature, MPV may be screened periodically in these patients, along with HbA1c and other measures to keep both physicians and patients aware of the inflammatory load of these diseases.

References

Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology & Metabolism. 2009;94(9):3171-3182.

Karagoz I, Aktas G, Yoldas H, et al. Association Between Hemogram Parameters and Survival of Critically Ill Patients. Journal of Intensive Care Medicine. 2017:0885066617703348.

Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. The American journal of gastroenterology. 2001;96(3):776-781.

Gasparyan AY, Sandoo A, Stavropoulos-Kalinoglou A, Kitas GD. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy. Rheumatology international. 2010;30(8):1125-1129.

Aktas G, Alcelik A, Tekce BK, Tekelioglu V, Sit M, Savli H. Red cell distribution width and mean platelet volume in patients with irritable bowel syndrome. Przeglad gastroenterologiczny. 2014;9(3):160.

Cakir L, Aktas G, Enginyurt O, Cakir SA. Mean platelet volume increases in type 2 diabetes mellitus independent of HbA1c level. Acta Medica Mediterranea. 2014;30:425.

Welsh P, Polisecki E, Robertson M, et al. Unraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approach. The Journal of Clinical Endocrinology & Metabolism. 2010;95(1):93-99.

Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes & development. 2007;21(12):1443-1455.

Chen S-B, Lee Y-C, Ser K-H, et al. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obesity Surgery. 2009;19(4):461-466.

Orea SI, Illán GF, Gonzálvez OM, et al. Soluble intercellular adhesion molecule-1 and C reactive protein after bariatric surgery. Endocrinologia y nutricion: organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2010;57(3):90-94.

Martos R, Valle M, Morales RM, Cañete R, Gascón F, Urbano MM. Changes in body mass index are associated with changes in inflammatory and endothelial dysfunction biomarkers in obese prepubertal children after 9 months of body mass index SD score loss. Metabolism. 2009;58(8):1153-1160.

Nijhuis J, Rensen SS, Slaats Y, Dielen FM, Buurman WA, Greve JWM. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity. 2009;17(11):2014-2018.

Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators of inflammation. 2010;2010.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.

Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-435.

Mortensen OH, Nielsen AR, Erikstrup C, et al. Calprotectin—a novel marker of obesity. PloS one. 2009;4(10):e7419.

Bochud M, Marquant F, Marques-Vidal P-M, et al. Association between C-reactive protein and adiposity in women. The Journal of Clinical Endocrinology & Metabolism. 2009;94(10):3969-3977.

Thorand B, Löwel H, Schneider A, et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Archives of internal medicine. 2003;163(1):93-99.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama. 2001;286(3):327-334.

Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First-trimester C-reactive protein and subsequent gestational diabetes. Diabetes care. 2003;26(3):819-824.

Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science. 2001;293(5535):1673-1677.

Papanas N, Symeonidis G, Maltezos E, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15(8):475-478.

Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. Journal of Diabetes and its Complications. 2009;23(2):89-94.


Article Views      : 0
PDF Downloads : 0